The news: Novo Nordisk is launching a tiered subscription program for self-pay Wegovy patients who obtain prescriptions through the drugmaker’s telehealth partners, including Ro, WeightWatchers, and Hims & Hers.

Patients can choose between three-, six-, or 12-month subscription plans for all Wegovy injection doses and the two highest-dose pill options, with longer plans offering lower monthly costs.

• For example, a 12-month subscription for the Wegovy shot saves members $1,200 annually.
• A 3-month plan for the same treatment saves $240 per year.
• Patients can opt out of the subscription even while it’s active, per CNBC.

Why it matters: Novo’s new pricing strategy aims to do two things: keep patients on Wegovy longer and attract new users with a subscription offering not available elsewhere.

Tackling early abandonment rates: Physicians report that over half of their GLP-1 patients discontinue treatment at some point within the first year, per December 2025 Sermo data. Top reasons for drop-off typically include medication cost, lack of tolerability for side effects, and achieving their weight loss goals. Novo is likely betting that adherence improves when patients have predictable drug pricing—subscription plans lock in costs even as drug prices fluctuate—and access to telehealth support for managing side effects.

Targeting cost-sensitive demand: Novo sees innovative pricing as a way to capture patients for its pill version before competing approved oral options hit the market. But despite strong early demand for Wegovy, many potential users could still be deterred by cost. A yearly subscription offering upwards of a 30% discount may help convert those hesitant patients.

Implications for the weight loss drug market: Novo’s new pricing model signals a shift toward a more retail- or tech-like sales approach—one it had been slow to embrace. However, it may be a stretch to assume that subscription pricing alone will improve patient adherence and retention. Unlike typical consumer products, pharmaceuticals involve unpredictable factors such as adverse reactions and evolving health conditions that can lead to changes in treatment.

The broader takeaway for players in the weight loss drug market is the need to proactively align with telehealth partners on post-prescription standards—ensuring providers are equipped to deliver personalized guidance based on patient history, closely monitor side effects, adjust regimens as needed, and transition patients to maintenance dosing when appropriate to sustain results.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.